Drugs / HLXL-Dan
HLXL-Dan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00755326 Comparator | Apr 2007 → Apr 2010 | osteoarthritis, knee | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLXL-Dan | “randomized to receive either high-dose HLXL-Dan (4000 mg/day for week 1-2, and 5600 mg/day for week 3-8) or placebo for 8 weeks.” PMID 26099553 ↗ Jun 2015 |
| Known as | HLXL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00755326 ↗ |
| Known as | Huo-Luo-Xiao-Ling (HLXL) Dan | “Huo-Luo-Xiao-Ling (HLXL) Dan” NCT00755326 ↗ |